Press Release, 12.08.2019

GILUPI Announces new Publications from multicenter prostate cancer study - TRANSCAN

The blood of cancer patients contains different types of tumor-derived materials that are susceptible to a downstream analysis for example in order to predict therapy response.

detailed analysis of tumor disease: intact circulating tumor cells (CTCs), cell-free circulating tumor DNA, tumor educated platelets and extracellular vesicles. Different techniques can isolate those biomarkers and are used as diagnostic and monitoring tools for cancer treatment. These blood-based tests (also called liquid biopsy) are a sensitive and less invasive alternative or complementary approach to tissue biopsies.

The first article, entitled: *Analysis of Circulating Tumor Cells in Patients with Non-Metastatic High-Risk Prostate Cancer before and after Radiotherapy Using Three Different Enumeration Assays* was published in Cancers 2019 issue 11 by Budna-Tukan **et al.** The research groups from Poznan University of Medical Sciences, Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre of Montpellier, University Medical Centre Hamburg-Eppendorf and the Wroclaw Medical University reported that among the compared methods the CellCollector was the method with the highest CTC detection rate.

The second article, entitled: In Vivo Detection of Circulating Tumor Cells in High-Risk Non-Metastatic Prostate Cancer Patients Undergoing Radiotherapy was published in Cancers 2019 issue 11 by Chen et al. The research groups from

The research program and educational curriculum of the European Liquid Biopsy Academy - ELBA[1], a MSCA ITN funded project (GA 765492), educates 15 early stage researchers in a range of applications and disease areas surrounding liquid biopsy. For this purpose, different companies perform trainings on state-of-the-art technologies and tools, diagnostic test development and further topics. As part of the educational program, GILUPI, together with other companies has successfully organized the first training workshop for liquid biopsy. During this training the students got familiar with the GILUPI CellCollector® for the isolation of CTCs and were trained in using this innovative technology to analyze CTCs.

Christian Jurinke, CEO of GILUPI commented: We are very proud to see the results from different prominent research groups concluding that our GILUPI CellCollector® is a superior . Our goal now is to innovative medical and diagnostic applications in an international and cooperative setting.

[1]

About GILUPI GmbH

GILUPI GmbH is a medical device company founded in 2006 with focus on the development and production of innovative products for the *in vivo* isolation of rare cells from the blood circulation. Currently, the main focus of GILUPI is the diagnostics market for cancer.

Individual oncological targeted therapies become increasingly important in personalized medicine. The identification of the right drug for the individual patient is todays challenge in clinical practice. To address this medical need, the GILUPI CellCollector® is used to enrich rare cells by immuno-capture directly in the patient's bloodstream. This methodology has proven to yield highest cell numbers and patient positivity rates in various cancer types. Applying diagnostic analyses ranging from immunostaining, DNA- and RNA-based methods, isolated cells can be characterized and/or analyzed down to a molecular level.

The GILUPI CellCollector® is the first *in vivo* CTC isolation product worldwide that is CE approved.

For further information visit www.gilupi.com